News

Watson anticipates beginning the shipment of the product immediately. The generic equivalent to Allergan’s Sanctura XR is indicated for the treatment of overactive bladder (OAB) with symptoms of

The HCMV portfolio includes letermovir (AIC246), an oral, late-stage antiviral candidate that is being investigated for the treatment and prevention of HCMV infection in transplant patients. Merck Research

As per the contract, Recipharm will conduct the formulation development work at the Recipharm Pharmaceutical Development site in Solna, near Stockholm. Astimex Pharma even has the chance to

Pursuant to the agreement, Pharmaron will offer discovery services in the areas of chemistry, drug metabolism and pharmacokinetics (DMPK), and efficacy screening to AstraZeneca. Financial details of the

The Specialized Programs of Research Excellence (SPORE) grant, spread over for a five-year period, is expected to identify new therapies to treat sarcoma. Sarcoma is a relatively rare

Led by Lutz Gissmann, the Division of Genome Modifications and Carcinogenesis set to begin assessing the therapeutic efficacy of the DKFZ’s HPV-specific plasmid DNA as part of the

Researchers of the firm have demonstrated the hLEC cells engraftment and bioactivity in vivo and their expandable capability. The newly issued ‘164 patent, which extends to 2022, has

The trial demonstrated that AUBAGIO could reduce the annualized relapse rate and prevent the progression of disability in patients with relapsing forms of multiple sclerosis (MS). The study

Abraxane phase II and phase III lung cancer trials lead investigator Mark Socinski said the FDA approval of Abraxane throws up more treatment options for all types of